Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Drs Psaty and Rennie1 discussed ethical imperatives against premature
discontinuation of clinical trials for financial reasons. They argued that
this causes harm by breaking the implicit and explicit agreements with research
participants, investigators, and the oversight bodies that approved the protocol.
Although the authors focused on industry-sponsored trials, their arguments
actually apply to all clinical research regardless of sponsorship.
Brass EP. Premature Termination of Clinical Trials. JAMA. 2003;290(5):595. doi:10.1001/jama.290.5.595-a